Decreased TNF levels and improved retinal ganglion cell survival in MMP-2 Null mice suggest a role for MMP-2 as TNF sheddase by De Groef, Lies et al.
Research Article
Decreased TNF Levels and Improved Retinal
Ganglion Cell Survival in MMP-2 Null Mice Suggest
a Role for MMP-2 as TNF Sheddase
Lies De Groef,1 Manuel Salinas-Navarro,1 Griet Van Imschoot,2,3
Claude Libert,2,3 Roosmarijn E. Vandenbroucke,2,3 and Lieve Moons1
1Laboratory of Neural Circuit Development and Regeneration, Animal Physiology and Neurobiology Section,
Department of Biology, KU Leuven, Naamsestraat 61, 3000 Leuven, Belgium
2Inflammation Research Center, VIB, FSVM Building, Technologiepark 927, 9052 Ghent, Belgium
3Department of Biomedical Molecular Biology, Ghent University, FSVM Building, Technologiepark 927, 9052 Ghent, Belgium
Correspondence should be addressed to Lieve Moons; lieve.moons@bio.kuleuven.be
Received 7 July 2015; Accepted 27 August 2015
Academic Editor: Ulrich Eisel
Copyright © 2015 Lies De Groef et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Matrix metalloproteinases (MMPs) have been designated as both friend and foe in the central nervous system (CNS): while being
involved in many neurodegenerative and neuroinflammatory diseases, their actions appear to be indispensable to a healthy CNS.
Pathological conditions in theCNS are therefore often related to imbalancedMMPactivities and disturbances of the complexMMP-
dependent protease network. Likewise, in the retina, various studies in animal models and human patients suggested MMPs to be
involved in glaucoma. In this study, we sought to determine the spatiotemporal expression profile ofMMP-2 in the excitotoxic retina
and to unravel its role during glaucoma pathogenesis. We reveal that intravitreal NMDA injection inducesMMP-2 expression to be
upregulated in the Mu¨ller glia. Moreover, MMP-2 null mice display attenuated retinal ganglion cell death upon excitotoxic insult
to the retina, which is accompanied by normal glial reactivity, yet reduced TNF levels. Hence, we propose a novel in vivo function
forMMP-2, as an activating sheddase of tumor necrosis factor (TNF). Given the pivotal role of TNF as a proinflammatory cytokine
and neurodegeneration-exacerbating mediator, these findings generate important novel insights into the pathological processes
contributing to glaucomatous neurodegeneration and into the interplay of neuroinflammation and neurodegeneration in the CNS.
1. Introduction
Thesubfamily of the gelatinases, consisting ofmatrixmetallo-
proteinase-2 (MMP-2, gelatinase A, 72 kDa type IV colla-
genase) and matrix metalloproteinase-9 (MMP-9, gelatinase
B, 92 kDa type IV collagenase), is the most extensively
studied subfamily of matrix metalloproteinases (MMPs). In
the central nervous system (CNS), their involvement in
Alzheimer’s disease, multiple sclerosis, amyotrophic lateral
sclerosis, epilepsy, meningitis, and so forth has been well
studied, leading to insights into their role in pathophysi-
ological processes such as blood-brain barrier disruption,
neuroinflammation, demyelination, neuronal cell death, and
brain edema [1–4]. Unfortunately, this has somewhat over-
shadowed their potential as beneficial modulators of CNS
development, plasticity, and repair [5].
Also in the eye, MMPs are needed for the development
and physiology of the lens, cornea, retina, sclera, and trabecu-
larmeshwork, but unrestrainedMMP activitymight underlie
a number of ocular pathologies and retinal degenerations,
including glaucoma [6–11]. In the retina, increased MMP-
9 activity in the ganglion cell layer (GCL), expressed by
either reactive astrocytes [10, 11] or retinal ganglion cells
(RGCs) [12, 13], plays a key role in the promotion of RGC
death. Increased MMP-9 expression/activity in the retina
was reported upon induction of ischemia-reperfusion injury
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[11, 13–16], N-methyl-D-aspartic acid (NMDA) and kainic
acid-mediated excitotoxicity [10, 12], optic nerve transection
[17], and ocular hypertension [18] in rodents. Moreover, this
increase in MMP-9 activity positively correlated with RGC
death, by promoting laminin degradation and detachment-
induced apoptosis of RGCs [13, 18, 19]. The ultimate confir-
mation of this detrimental role of MMP-9 was seen in MMP-
9 null mice, which were protected from laminin degradation
and RGC death after optic nerve ligation [14]. In contrast to
MMP-9, virtually nothing is known about the role of MMP-
2 in the healthy nor the glaucomatous retina. MMP-2 has
been reported being expressed by RGCs, Mu¨ller glia, and
astrocytes in the mouse retina and by RGC somata and axons
in primates [10, 20, 21], yet it is still under debate whether
MMP-2 becomes upregulated upon glaucomatous damage to
the retina or whether its expression levels remain unchanged
[10, 12, 15–17, 20]. Moreover, in contrast to MMP-9, MMP-
2 deficiency did not protect against RGC death in the optic
nerve ligation glaucoma model [14].
Here, we describe the spatiotemporal expression of the
gelatinases MMP-2 and MMP-9 in the retina of mice that
received an intravitreal injection of the glutamate analogue
NMDA in order to induce RGC death. This experimental
glaucoma model mimics excitotoxic damage to the retina
[22–27], as glutamate is the predominant excitatory neuro-
transmitter in the CNS and overstimulation of its receptors
leads to excessive Ca2+ influx and activation of apoptotic sig-
naling cascades. This excitotoxic injury is common to many
neurological disorders [28], including glaucoma [29–31], in
which the retinal neurodegeneration ties to the exquisite
sensitivity of the RGCs to glutamate and the glutamate
analogue NMDA. Next, we focused on MMP-2 and explored
its contribution to RGC death following NMDA-induced
excitotoxic retinal injury. Therefore, we investigated differ-
ential susceptibility to NMDA-induced RGC degeneration
in wild type and MMP-2 null mice and explored three
putative mechanisms by which MMP-2 could contribute to
RGC death: (1) laminin degradation leading to detachment-
induced apoptosis, (2) glial reactivity, and (3) potentiation of
glutamate excitotoxicity by tumor necrosis factor (TNF).
2. Methodology
2.1. Experimental Animals. All studies were conducted in
compliance with the European Communities Council Direc-
tive of 22 September 2010 (2010/63/EU) and the Belgian
legislation (KB of 29May 2013) and were approved by the KU
Leuven institutional ethical committee. Adult (2-3 months)
wild type, MMP-2 null [32], and MMP-9 null mice [33], all
with a C57Bl6/N genetic background, were obtained from
the university breeding colony. Wild type, MMP-2 null, and
MMP-9 null mice were genotyped to confirm homozygosity,
as described by [32, 33]. Animals were kept under a 12/12
light-dark cycle and had ad libitum access to food and water.
2.2. SurgicalProcedures. Allsurgicalprocedureswere performed
under general anesthesia (i.p. 75mg/kg body weight keta-
mine, Anesketin, Eurovet; i.p. 1mg/kg medetomidine, Domi-
tor, Pfizer). After the procedure, anesthesia was reversed by
means of atipamezole (i.p. 1mg/kg, Antisedan, Pfizer), and
antibiotic ointment (tobramycin 3mg/g, Tobrex, Alcon) was
applied to avoid corneal desiccation and infection of the eye.
In order to exclude contralateral effects, which have been
reported, for example, for GFAP expression and microglia
reactivity [34–36], untreated eyes from a separate cohort of
untreated animals served as controls.
2.2.1. Intravitreal NMDA Injection. Intravitreal injection was
performed as described [24]. Briefly, NMDA (20mM or
4.0mM in phosphate-buffered saline (PBS); Sigma-Aldrich)
was injected into the superior quadrant of the right eye using
a glass capillary with a 50–70𝜇m outer diameter, connected
to a Hamilton syringe. The needle tip was inserted into
the vitreous chamber 1mm behind the limbus under a 45-
degree angle to avoid damage to the lens, and a total volume
of 2 𝜇L (0.5 𝜇L/sec) was injected. In addition to general
anesthesia, eye drops with topical anesthesia (oxybuprocaine
0.4%, Unica¨ıne, The´a) were given. Animals were sacrificed at
1 day postinjury (dpi).
2.2.2. Optic Nerve Crush. Optic nerve crush (ONC) was
performed as described [37]. Briefly, an incision was made in
the skin overlying the superior orbital rim, the superoexternal
orbital contents were dissected, and the superior and external
rectus muscles were transected. The exposed optic nerve
was then crushed 1mm from the globe with a watchmaker’s
forceps for 10 sec. Fundoscopy was performed before and
after the procedure to assess integrity of retinal perfusion.
Animals were sacrificed at 4 dpi.
2.3. Immunohistochemistry
2.3.1. MMP Immunostaining on Cryosections. Mice were
deeply anaesthetized (i.p. 30mg/kg sodium pentobarbital,
Nembutal, Ceva) and perfused transcardially with 4% PFA.
Eyes were dissected and postfixed overnight in 4% PFA,
and the cornea and lens were removed. The remainder
posterior segment of the eye was cryoprotected in a 10%-
20%-30% sucrose series (in PBS) and embedded in Tissue-
Tek optimal cutting temperaturemedium (Sakura Finetek) to
make transverse cryosections (10 𝜇m).
Antigen retrieval was performed by heating the sections
in citrate buffer (10mM[pH6.0]) for 20min at 95∘C, followed
by a 20min cooling down. Next, sections were incubated
for 20min in 0.3% hydrogen peroxidase (in methanol) to
saturate endogenous peroxidases and subjected to a 1 h
blocking step with 20% preimmune serum. Sections were
incubated overnight with the primary antibody at room
temperature. Based on a comparison of antibody specificity
by De Groef et al. [38], the following antibodies were
used: rabbit anti-MMP-2 (Millipore, ab19167) (1 : 300) and
mouse anti-MMP-9 (Abcam, ab58803) (1 : 300). Secondary
IgG antibodies were conjugated to biotin (Dako) (1 : 300)
and applied for 45min, followed by 30min incubation with
streptavidin-horse radish peroxidase (HRP) (Perkin-Elmer)
(1 : 100). Finally, fluorescein isothiocyanate tyramide signal
amplification was performed according to themanufacturer’s
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instructions (Perkin-Elmer). Sections were rinsed with Tris-
buffered saline (TBS) in between steps, and preimmune
serum and antibodies were diluted in 0.5% blocking solu-
tion (Perkin-Elmer). 4󸀠,6-Diamidino-2-phenylindole (DAPI)
(1 𝜇g/mL in PBS, AppliChem) was used as a fluorescent
nuclear counterstaining and sections were mounted using
Mowiol antifading medium (10% Mowiol 4–88 (Sigma-
Aldrich), 40% glycerol, and 0.1% 1,4-diazabicyclo-[2, 2, 2]-
octane in 0.2M Tris-HCl [pH 8.5]). All images were taken
with an inverted confocal microscope (FV1000, Olympus)
and were processed with FluoViewer (Olympus) and Photo-
shop CS2 (Adobe) software.
2.3.2. Brn3a Immunostaining on Retinal Flat Mounts. Mice
were deeply anaesthetized (i.p. 30mg/kg sodium pentobar-
bital, Nembutal, Ceva) and sacrificed by cervical dislocation.
Next, eyes were dissected and fixed for 1 h in 4% phosphate-
buffered paraformaldehyde (PFA). The retina was dissected
and flat-mounted and again fixed for 1 h in 4% PFA. Prior
to immunohistochemistry, retinal flat mounts were rinsed in
PBS with 0.5% Triton X-100 for 3 times for 10min.
Retinas were frozen for 15min at −80∘C, before applying
the primary goat anti-Brn3a antibody (Santa Cruz, C-20, sc-
31984) (1 : 750), which has been shown to selectively label
RGCs [39, 40]. On the next day, a secondary rabbit anti-
goat IgG antibody conjugated to Alexa fluorophore-488 (Life
Technologies) (1 : 500) was applied for 2 h. Retinal flatmounts
were rinsed with PBS with 0.5% Triton X-100 in between
steps, and all antibodies were diluted in PBS containing 2%
Triton X-100 and 2% rabbit preimmune serum. Mosaic z-
stack images of the entire retina were taken with a multi-
photon microscope (BX61WI, Olympus), equipped with a
MaiTai HP DeepSee laser (690–1020 nm, Spectra Physics)
and FluoViewer 4.0 software (Olympus).
2.4. Gelatin Gel Zymography. Micewere deeply anaesthetized
(i.p. 30mg/kg sodium pentobarbital, Nembutal, Ceva) and
sacrificed by cervical dislocation. Retinas were quickly dis-
sected and homogenized in ice-cold lysis buffer (50mM
Tris-HCl [pH 7.6], 5mM CaCl
2
, 150mM NaCl, 0.05% Brij-
35 (Sigma-Aldrich), 1% Triton X-100, and 100 𝜇M phenyl-
methylsulfonyl fluoride), supplemented with an EDTA-free
proteinase inhibitor cocktail (Roche). Upon homogenization,
samples were centrifuged, supernatant was collected, and
protein concentrations weremeasured withQubit fluoromet-
ric quantitation (Life Technologies).
Aliquots containing 120 𝜇g of total proteins were incu-
bated with 50𝜇L gelatin-conjugated Sepharose beads (gelatin
Sepharose 4B, GE Healthcare) in equilibrating buffer (0.5M
NaCl, 10mM CaCl
2
, and 0.01% Tween-20 in TBS) for
20min at room temperature, for affinity precipitation. Next,
the beads were rinsed twice with TBS containing 0.5M
NaCl, 10mM CaCl
2
, and 0.05% Tween-20 and once with
TBS containing 10mM CaCl
2
and 0.05% Tween-20. Finally,
gelatinases were eluted with 20𝜇L zymogram loading buffer
(Novex Tris Glycine SDS Sample Buffer, Life Technologies)
and loaded on a 10% gelatin gel (Novex, Life Technologies)
for electrophoresis. Gels were incubated in 2.5% Triton X (in
water) for 30 minutes and developed for 2 days at 37∘C in
TBS containing 10mM CaCl
2
and 1.25% Triton X-100. After
staining with Coomassie blue (0.5% in a mixture of 9 : 9 : 2
methanol, water, and acetic acid) for 3 h, gels were destained
for 2 h (in a mixture of 9 : 9 : 2 ethanol, water, and acetic
acid) and imaged with the ChemiDoc MP Imaging System
(BioRad). Quantification was performed with Image Lab 4.1
(BioRad).
2.5. Western Blotting. Mice were deeply anaesthetized (i.p.
30mg/kg sodium pentobarbital, Nembutal, Ceva) and sacri-
ficed by cervical dislocation. Retinas were quickly dissected
and homogenized in ice-cold lysis buffer (50mM Tris-HCl
[pH 7.5], 10mMCaCl
2
, 150mMNaCl, 0.05% Brij-35 (Sigma),
and 1% Triton X-100), supplemented with an EDTA-free
proteinase inhibitor cocktail (Roche). Upon homogenization,
samples were centrifuged, supernatant was collected, and
protein concentrations weremeasured withQubit fluoromet-
ric quantitation (Life Technologies).
Retinal homogenates (25 𝜇g) were loaded on 4–12%
SDS-PAGE and transferred onto a polyvinylidene fluoride
membrane. After 2 h of blocking with 5% Amersham ECL
Blocking Agent (GEHealthcare), membranes were incubated
overnight at room temperature with the primary antibody.
The following antibodies were used: rabbit anti-laminin
(Sigma-Aldrich, L9393) (1 : 1000) and rabbit anti-glial fibril-
lary acidic protein (GFAP) (Dako, Z0334) (1 : 20000). On the
next day, membranes were incubated for 45min with HRP-
labeled secondary goat anti-rabbit IgG antibody (1 : 20000
for laminin, 1 : 100000 for GFAP) and protein bands were
visualized with the ChemiDoc MP Imaging System (Bio-
Rad), using a luminol-based enhanced chemiluminescence
(ECL) kit (Thermo Scientific). All antibodies were diluted
in 5% Amersham ECL Blocking Agent (GE Healthcare)
(in TBS). Data were normalized using a total protein stain
with Coomassie blue and quantification was performed with
Image Lab 4.1 (BioRad).
2.6. TNF Immunoassay. Mice were deeply anaesthetized
(i.p. 30mg/kg sodium pentobarbital, Nembutal, Ceva) and
sacrificed by cervical dislocation. Retinas were quickly dis-
sected and homogenized in ice-cold PBS, supplemented with
an EDTA-free proteinase inhibitor cocktail (Roche). Upon
homogenization, samples were centrifuged, supernatant was
collected, and protein concentrationsweremeasuredwith the
Pierce BCA protein assay kit (Life Technologies).
Quantification of TNF in retinal homogenates was per-
formed using the Bio-Plex cytokine immunoassay (BioRad),
according to the manufacturer’s instructions. For each sam-
ple, 50 𝜇g of total protein was used.
2.7. Quantification of RGC Survival. RGC density (number
of RGCs/mm2) was evaluated on entire retinal flat mounts
after immunostaining for Brn3a and automatically computed
using Fiji software [41] and an in-housemademacro. Briefly, a
rolling ball background subtraction was used and, after local
thresholding, Brn3a immunopositive RGCs were automati-
cally counted, based on selection criteria for size and shape
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(circularity). The retinal flat mount was manually outlined
and its surface was computed, to yield the total number of
RGCs over the total surface of the retina.
2.8. Statistics. Normal distribution was verified using a
Kolmogorov-Smirnov test and parallel equal variance
between groups was tested. Outliers were identified and
excluded, based on Grubbs test. Zymography data were
analyzed using a one-way ANOVA with Dunnett’s post hoc
multiple comparisons test. Western blot data for laminin
and GFAP were analyzed using a two-way ANOVA. RGC
survival was analyzed using Student’s 𝑡-test. TNF levels were
analyzed using both two-way ANOVA and Student’s 𝑡-test.
A probability level (𝛼-level was set to 0.05) of <0.05 was
accepted as statistically significant (∗𝑝 < 0.05, ∗∗𝑝 < 0.01,
and ∗∗∗𝑝 < 0.005). All data are presented as mean ± SEM.
Statistical analyses were performed using GraphPad Prism 6
(GraphPad Software).
3. Results
3.1. Spatiotemporal Expression Patterns ofMMP-2 andMMP-9
in the Excitotoxic Mouse Retina. Expression levels of MMP-
2 and MMP-9 were studied in the retina under physiological
conditions and within the first 24 h after intravitreal admin-
istration of NMDA. In the naive retina, gelatin zymography
revealed that both gelatinases were present in their proform
and nomatureMMP-2 orMMP-9was seen. Upon excitotoxic
injury to the retina, the expression of the proform of both
gelatinases was upregulated. For MMP-9, this resulted in
a 20-fold upregulation of pro-MMP-9 expression and a
significant rise in mature MMP-9 at 18 hours postinjection
(hpi) (Figure 1(d)). For MMP-2, expression of the proform
was nearly 2.5 times upregulated at 18 hpi, yet mature MMP-
2 remained below detection levels (Figure 1(a)). Remarkably,
the expression of mature MMP-9, pro-MMP-9, and pro-
MMP-2 had returned to baseline levels by 24 hpi.
Immunostaining for MMP-2, at its peak of expression
(18 hpi), revealed an increased labeling of activated astro-
cytes and/or Mu¨ller glia as compared to the naive retina
(Figures 1(b)-1(c)) [38]. On MMP-9 immunostainings, an
increased number ofMMP-9 immunopositivemicroglia near
the borders of the inner nuclear layer (INL) were seen [38]
and augmented MMP-9 immunoreactivity in the plexiform
layers. Furthermore, while in the naive retina RGCs were
only sporadically labeled for MMP-9 [38], the majority of
RGCs were MMP-9 immunopositive in the excitotoxic retina
(Figures 1(e)-1(f)).
3.2. MMP-2 Deficiency Attenuates Excitotoxic RGC Death.
Given the upregulated expression ofMMP-2 upon excitotoxic
retinal damage seen in this study, we next investigated
whether MMP-2 null mice also displayed altered sensitivity
to experimentally induced RGC death. Two independent
experiments, with varying severities of RGC death induced
by different doses of NMDA, were performed to investigate
whether wild type and MMP-2 null mice are differentially
susceptible to NMDA-induced RGC death. In the first high-
dose experiment, wild type mice displayed 58 ± 8% RGC
survival at 24 hpi, yet MMP-2 null mice proved to be more
resistant to RGC death and displayed 78 ± 2% RGC survival
(𝑝 < 0.05).The second low-dose experiment revealed 85±7%
RGC survival in the wild type mice and yet no significant
RGC death (93±7% survival) inMMP-2 null mice (𝑝 < 0.05)
(Figure 2) (Table 1). These data thus reveal that RGC death is
attenuated in MMP-2 deficient animals.
3.3. Potential Mechanisms Underlying Increased
RGC Survival in MMP-2 Null Mice
3.3.1. Laminin-Integrin Signaling. MMP-9 null mice, in con-
trast toMMP-2 null mice, were reported to be protected from
RGC death induced by optic nerve ligation, and this was
accompanied by preservation of the laminin composition of
the inner limiting membrane and laminin-integrin survival
signaling in the RGCs [13, 14, 18, 19]. Given that MMP-2
is also a gelatinase and shares many substrates with MMP-
9, we performed a Western blot for laminin 𝛽1/𝛾1, to see
whether (1) laminin is degraded after NMDA injection, as
was shown in the optic nerve ligation model, and whether
(2) laminin is differentially present in the retina of wild type
versus MMP-2 null mice. Western blot indicates, however,
that intravitreal injection of NMDA did not affect laminin
integrity in the retina, not in wild type nor MMP-2 null
mice (𝑝 = 0.39) (Figure 3(a)). Notably, in line with the
findings obtained in the optic nerve ligation model [14],
MMP-9 null mice displayed increased RGC survival after
ONC (𝑝 < 0.001) (Figure 3(c)), while MMP-2 mice did
not (Figure 3(b)) (Table 2). Altogether, these observations
suggest that RGC death might be evoked by a different
mechanism in theONC/optic nerve ligationmodel versus the
NMDA-induced excitotoxicity model. Nevertheless, our data
suggest that laminin-dependent survival signaling in RGCs
does not contribute to the neuroprotective effect of MMP-2
deficiency.
3.3.2. Glial Reactivity. While neuronal cell death is the pri-
mary hallmark of neurodegeneration, it is also accompanied
by reactivity of the glial cells. This gliosis is believed to serve
both detrimental and beneficial functions and may have a
major impact on the outcome of neurodegenerative events.
The intermediate filament protein GFAP has traditionally
been considered the most sensitive early indicator of reactive
gliosis [42] and reflects the hypertrophic response of Mu¨ller
glia in the injured retina. Given its glial expression pattern
and increased expression during RGC death/retinal gliosis,
which closely resembles the increase in GFAP expression that
is characteristic of glial reactivity following retinal injury, we
therefore investigated whether MMP-2 might be involved in
reactive gliosis. Western blot analysis of GFAP expression
on retinal samples isolated at 6 hpi of NMDA indicated
that retinal GFAP levels tended to increase as compared to
baseline GFAP expression (𝑝 = 0.24). Both wild type and
MMP-2 null mice appeared to mount a glial response within
6 h after NMDA injection (𝑝 = 0.28), characterized by
a ∼30% increase in GFAP expression (Figure 4(a)). Taken
together, glial reactivity seemed to be unaffected in MMP-2
null mice.
Mediators of Inflammation 5
300
200
100
0
Re
lat
iv
e e
xp
re
ss
io
n 
(%
)
Pro-MMP-2
Pro-MMP-2
∗∗
0 6 12 18 24
Hours after injection
M
M
P-
2
Gelatin zymography
(a)
IHC naive
(b)
IHC-NMDA, 18hpi
(c)
3000
2000
1000
0
Re
lat
iv
e e
xp
re
ss
io
n 
(%
)
Pro-MMP-9
Active MMP-9
Pro-MMP-9
Active MMP-9
∗∗∗
∗∗∗
∗∗∗
0 6 12 18 24
Hours after injection
M
M
P-
9
Gelatin zymography
(d)
IHC naive
(e)
IHC-NMDA, 18hpi
(f)
Figure 1: Expression profiles of MMP-2 and MMP-9 in the excitotoxic mouse retina. (a) Upon excitotoxic injury to the retina, pro-MMP-2
expression, as revealed by gelatin zymography, was upregulated, reaching maximum expression at 18 hpi and returning to baseline levels by
24 hpi. (b) Immunohistochemical (IHC) staining for MMP-2 (green) in the naive retina. (c) Immunostaining for MMP-2 revealed that the
increased MMP-2 expression at 18 hpi localized to the activated astrocytes and/or radial processes of the Mu¨ller glia. (d) Gelatin zymography
disclosed that, upon excitotoxic injury to the retina, pro-MMP-9 steeply increased to reach a maximum at 18 hpi, accompanied by a lower
peak of activated MMP-9. At 24 hpi, both mature and pro-MMP-9 levels had returned to baseline. (e) Immunostaining for MMP-9 (green)
in the naive retina. (f) Upon excitotoxic injury to the retina, an increased number of MMP-9+ microglia and RGCs, and augmented MMP-9
immunoreactivity in the plexiform layers were observed. Scale bars, 20 𝜇m.
3.3.3. TNF Signaling. The proinflammatory cytokine TNF
(TNF𝛼) is believed to play a central role in glaucomatous neu-
rodegeneration [43]. Moreover, its contribution to NMDA-
induced RGCdeath has beenwell described [24], as well as its
inducing effects on Mmp gene transcription [44]. Inversely,
several MMPs, including MMP-2, can activate pro-TNF
[45]. Quantification of TNF by means of an immunoassay,
preferentially detecting soluble TNF, revealed that baseline
TNF levels were reduced by more than 60% in MMP-2 null
mice. Intravitreal injection of NMDA induced a significant
increase in TNF at 6 hpi (𝑝 < 0.05), both in wild type and
MMP-2 null mice. However, while an 85% increase was seen
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Figure 2: MMP-2 null mice are less susceptible to NMDA-induced RGC death. (a) Quantification of the number of Brn3a+ RGCs in two
independent experiments (20mM or 4.0mM NMDA), during which different severities of RGC death were evoked, revealed that RGC
death is attenuated in MMP-2 null mice (mean ± SEM,𝑁 ≥ 5, Student’s 𝑡-test). (b) RGC survival was assessed at 24 hpi by means of Brn3a
immunolabeling of viable RGCs. Scale bar, 100𝜇m.
in wild type mice, TNF levels augmented by only 18% in
MMP-2 null mice, resulting in TNF levels still below the
baseline levels seen in wild type mice (Figure 4(b)). Overall,
TNF activationwas suppressed inMMP-2nullmice, resulting
in lower baseline TNF levels and reduced activation upon
excitotoxic injury to the retina.
4. Discussion
In summary, this study reported four major findings. First,
NMDA exposure caused induction of gelatinase expres-
sion/activity in the retina, including increased MMP-2
expression inMu¨ller glia. Second, RGCdegeneration induced
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Table 1: Quantification of RGC survival in wild type and MMP-2 null (MMP-2−/−) mice, after intravitreal injection of NMDA (1 dpi). RGC
densities (RGCs/mm2) per retina are depicted.𝑁, number of animals.
Experiment I Experiment II
Naive 20mMNMDA Naive 4.0mMNMDA
Wild type MMP-2−/− Wild type MMP-2−/− Wild type MMP-2−/− Wild type MMP-2−/−
3243 2960 1428 3110 3267 3228 3019 2931
3761 3773 1207 2723 3471 3225 3038 3009
3087 3465 1759 2955 2990 3294 2806 3418
3428 3687 2830 2836 3465 3354 2759 2927
3455 3417 2004 3141 3439 3557 2379 2827
2843 2576 3646 3416 2787 3458
3046 3276
2990 3033
Mean 3380 3781 1967 2953 3380 3346 2853 3110
SEM 144 461 259 79 92 51 79 85
𝑁 5 6 6 5 6 6 8 8
by intravitreal injection of NMDA was diminished in MMP-
2 null mice. Third, glial hypertrophy and laminin integrity
were unaffected in the retina of wild type versus MMP-2 null
mice exposed to NMDA. Fourth, both baseline TNF levels
and the upregulation of TNF levels upon intravitreal NMDA
injection were reduced in MMP-2 null mice.
4.1. MMP-2 Expression Is Upregulated in the Excitotoxic
Mouse Retina. Available expression data and functional
studies of MMP-2 in the retina are either inconclusive or
lacking. Whereas some report no changes in MMP-2 activ-
ity/expression after excitotoxic injury, ischemia-reperfusion,
or optic nerve transection [12, 15, 17], others described
increased expression/activity in the retina at 6 h after
ischemia-reperfusion injury or excitotoxicity [10, 16]. By
means of gelatin zymography, we revealed a clear upregula-
tion of pro-MMP-2 expression upon excitotoxic retinal injury
that reached a maximum at 18 hpi and returned to baseline
levels by 24 hpi. Furthermore, immunostaining for MMP-2
revealed thatMMP-2 expression is at all times confined to the
Mu¨ller glia. While both Western blot [38] and zymography
results indicate that MMP-2 is present in its proform in the
naive retina, it might seem surprising that no mature MMP-
2 was detected upon upregulation of MMP-2 expression at
18 hpi. However, whereas gelatin zymography is believed to
be themost specific technique to quantifyMMP-2 expression
[46], we believe that this is due to the detection limits of the
gelatin zymography.
4.2. Glial Reactivity Is Preserved in MMP-2 Null Mice. In
the healthy retina, Mu¨ller glia support neuronal function
and metabolism by providing trophic support, removing
metabolic waste, maintaining retinal homeostasis, and pre-
serving the blood-retinal barrier (BRB). At the same time,
they also support synaptic activity, by recycling neurotrans-
mitters, supplying neurotransmitter precursors, and releasing
gliotransmitters. In case Mu¨ller glia become activated, which
happens upon virtually every pathological stimulus, theymay
sustain the survival of photoreceptors and neurons but may
also contribute to neuronal degeneration. Indeed, glial reac-
tivity, sometimes described as a low-grade inflammation,may
help to maintain the CNS integrity, by filling gaps created by
degenerating neurons, restoring damaged protective barriers,
inducing the release of neurotrophic factors, clearance of
excess extracellular glutamate, and so forth.However, chronic
or exacerbated gliosis is also correlated with glial metabolic
dysfunction, altered neuronal electrophysiology, suppression
of regeneration due to glial scarring and inflammation-
induced BRB dysfunction, oxidative stress, mitochondrial
dysfunction, and so forth [47–49]. Taken together, neuroin-
flammation and neurodegeneration are intrinsically inter-
twined, and glial reactivity has a profound impact on the
outcome of neurodegenerative processes.
Based on its expression pattern in Mu¨ller glia, we
explored a potential role for MMP-2 during reactive gliosis.
Notably, in contrast to our findings, MMP-2 null mice have
been shown to display impaired structural and functional
recovery after spinal cord injury due to increased gliosis [50].
Also, TNF has been described to reduce GFAP expression
[51, 52]. Western blot experiments revealed a trend towards
an increased GFAP expression at 6 hpi, suggesting that
gliosis occurred in response toNDMA-induced retinal injury.
Nevertheless, no difference in GFAP upregulation was found
in wild type versus MMP-2 deficient mice, and no baseline
differences were seen either. Wild type and MMP-2 null
animals both thus initiate reactive gliosis to the same extent,
at least as analyzed via intermediate filament expression.
4.3. Low TNF Levels and Decreased NMDA-Induced RGC
Death in MMP-2 Null Mice. MMP-2 deficiency was reported
to have no effect on RGC survival upon optic nerve ligation
[14], a finding we confirmed in the ONC model. In contrast,
our results revealed attenuated RGC death in MMP-2 null
animals exposed to yet another glaucoma model, that is,
excitotoxic RGC death induced by an intravitreal injec-
tion of NMDA. Strikingly, these MMP-2 null mice showed
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Figure 3: Differential mechanisms underlie RGC death in NMDA-induced excitotoxicity and optic nerve crush models. (a) Western blot
for laminin (200–220 kDa) on retinal samples from wild type and MMP-2 null mice, either naive or subjected to the NMDA-induced
excitotoxicity model, revealed no differences in laminin expression at 18 hpi (mean ± SEM, 𝑁 = 3, one-way ANOVA). (b) No difference
in RGC death after ONC was seen in wild type versus MMP-2 null mice (mean ± SEM, 𝑁 ≥ 6, Student’s 𝑡-test). (c) Four days after ONC,
MMP-9 null mice revealed attenuated RGC death as compared to wild type mice (mean ± SEM,𝑁 ≥ 6, Student’s 𝑡-test). (d) Representative
pictures of Brn3a immunostaining, revealing differential RGC death after ONC in wild type and MMP-2 null versus MMP-9 null mice. Scale
bar, 100𝜇m.
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Table 2: Quantification of RGC survival in wild type, MMP-2 null (MMP-2−/−), andMMP-9 null (MMP-9−/−) mice, after ONC (4 dpi). RGC
densities (RGCs/mm2) per retina are depicted.𝑁, number of animals.
Naive ONC
Wild type MMP-2−/− MMP-9−/− Wild type MMP-2−/− MMP-9−/−
3393 3059 3551 2317 2327 2342
3265 2928 3458 2473 2262 2663
3660 3580 3481 2785 2606 2939
3309 3810 3932 1952 2154 2695
3187 3759 1825 2856 2641 3122
3464 2938 2240 2463 2149 2880
2192 2230 2663
3209
Mean 3380 3346 2954 2475 2338 2813
SEM 68 169 316 134 77 99
𝑁 6 6 7 6 7 8
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Figure 4: GFAP and TNF levels in wild type versus MMP-2 null mice, at baseline and 6 h after injection of NMDA. (a)Western blot revealed
a trend towards increased GFAP expression upon intravitreal injection of NMDA, yet no differences between wild type andMMP-2 null mice
(mean ± SEM,𝑁 ≥ 7, two-way ANOVA). (b) Baseline TNF levels were lower in MMP-2 null mice as compared to wild type mice (mean ±
SEM,𝑁 ≥ 6, #𝑝 < 0.05, Student’s 𝑡-test). At 6 hpi, TNF levels had increased in both wild type and MMP-2 null mice; yet MMP-2 null mice
still expressed significantly less TNF than wild type mice (mean ± SEM,𝑁 ≥ 6, one-way ANOVA).
reduced levels of TNF, a proinflammatory cytokine with a
well-documented neurodegeneration-exacerbating function
in glaucoma [43].
While MMP-2 null animals displayed a clearly dimin-
ished TNF upregulation in response to excitotoxic retinal
injury, the significant difference in baseline TNF levels
suggested that already under physiological conditions TNF
expression/activity was disturbed in MMP-2 deficient mice.
This is likely to be related to the role of MMPs, including
MMP-2, as activators of pro-TNF. Indeed, although TNF
converting enzyme (TACE) is the main metalloproteinase
involved in TNF activation, it has been shown that TACE
and MMPs play complementary roles in shedding of the
26 kDa transmembrane precursor protein of TNF to release
the soluble, biologically active 17 kDa C-terminal part from
the cell membrane [44, 45, 53–55]. Interestingly, activator
protein-1 (AP-1) binding site(s) in their promoter region
render mostMmp genes responsive to changes in the amount
and/or activity of corresponding transactivators, such as
TNF. In addition, the Mmp2 gene promotor also contains a
functional binding site for p53, a putative mediator of TNF-
induced apoptosis, and activation of pro-MMP-2 has been
shown to be stimulated via TNF-nuclear factor 𝜅-light-chain-
enhancer of activated B cells (NF-𝜅B) signaling [56, 57].
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Figure 5: Mechanisms of TNF-induced neurodegeneration in the glaucomatous retina. In the glaucomatous retina, bioactive, soluble TNF is
released by theMu¨ller glia. Upon binding to its receptor TNF-R1 on the RGCs, TNF induces apoptosis, via activation of the caspase (caspase-
8) signaling cascade, loss of mitochondrial membrane potential, and generation of reactive oxygen species. On the other hand, TNF is also
involved in a complex interplay between proinflammatory, proapoptosis, and prosurvival pathways, which indirectly affect RGC survival, via
nitric oxide production,modulation of neuronal excitability and excitotoxicity, expression and release ofMMPs (includingMMP-9), synthesis
and secretion of vasoactive endothelin-1, amyloid-beta neurotoxicity, BRB disruption, and neurotoxicity of secreted cytokines and recruited
microglia and T-cells. Notably, in this paper, we propose a novel in vivo function for MMP-2, as an activating sheddase of TNF. Drawings by
Ramon Y. Cajal.
As such, a complex regulatory feedback loop connecting
TNF activity andMMP-2 expression seems to be established,
which might augment the reduction in TNF shedding and
RGC vulnerability in MMP-2 null mice even more.
4.4. Neuroinflammation and Neurodegeneration in the Retina:
A Central Role for TNF. Glial production of TNF and
expression of its death receptor (TNF receptor-1, TNF-R1)
on RGCs and their axons are known to be upregulated in
the retina and optic nerve of glaucoma patients and animals
with experimentally induced glaucoma [43, 58, 59] and
may induce RGC death via multiple mechanisms (Figure 5).
These include direct pathways to RGC death, via binding
of glial TNF to TNF-R1 on RGCs, such as caspase 8-
dependent activation of the apoptosis cascade, mitochondrial
dysfunction leading to the release of mitochondrial cell
death mediators (cytochrome c, apoptosis inducing factor),
and generation of reactive oxygen species [43, 49]. On the
other hand, this potent immunomediator is also an essential
signaling molecule in the interplay between neuroinflamma-
tory and neurodegenerative events [60]. Glial reactivity and
TNF activity in the glaucomatous retina can lead to nitric
oxide production, modulation of neuronal excitability and
excitotoxicity, release of MMP-9, BRB disruption, synthe-
sis and secretion of vasoactive endothelin-1, amyloid-beta
neurotoxicity, direct neurotoxicity of secreted cytokines, and
indirect neurotoxicity by recruited microglia and T-cells [43,
49, 60]. Moreover, TNF also has a direct impact on Mu¨ller
glia function, via TNF-induced release of inflammatory
mediators, reactive oxygen species, and prostaglandins and
even suppression of intermediate filament expression and
Mu¨ller glia metabolism [60–62].
The impact of the immunomodulatory and neurotoxic
actions of TNF on RGC death was illustrated in several in
vitro studies and experimental glaucoma models [43, 63].
For instance, in case of an excitotoxic insult to the retina,
NMDA-induced activation of NF-𝜅B and production of TNF
in Mu¨ller glia were shown to result in RGC death. On the
other hand, TNF null mice and mice that had received
pharmacological anti-TNF treatment revealed remarkably
reduced RGC degeneration [24]. Likewise, TNF-R1 null
mice showed significantly less RGC degeneration after ONC,
especially during the period correlated with glial activation
and secondary neurodegeneration [64]. These data confirm
the importance of TNF in glaucomatous neurodegeneration
and indicate that inhibition of TNF shedding, for example, by
deletion ofMmp2, can indeed profoundly affect the outcome
of RGC degeneration.
4.5. Gelatinase Expression Is Upregulated in the Glaucomatous
Mouse Retina and Yet Plays a Different Role Depending on the
Kind of Injury. Spatiotemporal mapping of MMP-9 expres-
sion/activity revealed that MMP-9 expression and activity
rose as soon as 6 hpi, reaching a maximum at 12–18 hpi,
and returned to baseline levels at 24 hpi, in the excitotoxic
retina. The rise in MMP-9 activity was mainly situated in
the GCL, where the number of MMP-9+ RGCs remarkably
increased, as well as in activated microglia, whose num-
bers also augmented in the excitotoxic retina. Accordingly,
several studies in rodent models of glaucoma, induced by
ischemia-reperfusion injury [11, 13–16], N-methyl-D-aspartic
acid (NMDA), and kainic acid-mediated excitotoxicity [10,
12], optic nerve transection [17], and ocular hypertension
[18], revealed increased MMP-9 activity in the retina, which
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positively correlated with RGC death. This elevated MMP-
9 activity in the GCL was shown to play a key role in the
promotion of RGC death, as the resulting degradation of
laminin abrogated integrin-mediated survival signaling and
ultimately led to a decreased expression of antiapoptotic
Bcl-xL and detachment-induced apoptosis of RGCs [13, 18,
19]. Analogous to observations in MMP-9 null mice that
underwent optic nerve ligation [14], we observed (partial)
protection from RGC death in MMP-9 null mice 4 days after
ONC, a model bearing high similarities to the optic nerve
ligation model.
Remarkably, integration of the data obtained in the
present study and those by Chintala et al. [14] points out
that MMP-2 null mice are vulnerable to optic nerve injury-
induced RGC death and yet are protected from NMDA-
induced RGC death. We therefore postulate that the mech-
anisms underlying RGC death in the NMDA-induced glau-
coma model and in the optic nerve ligation/crush models
are very distinct and that MMP-2 andMMP-9 are apparently
differentially involved in these different types of glaucoma-
tous injury. Indeed, while RGC death was linked to laminin
degradation in the optic nerve ligation model, the present
data showed that laminin expression was preserved in the
retina of mice subjected to the NMDAmodel.
5. Conclusion and Future Perspectives
In this paper, we revealed that intravitreal injection ofNMDA
induced a transient increase in MMP-2 in the Mu¨ller glia
and that MMP-2 null mice were more resistant to NMDA-
induced RGC death than wild type animals. Intriguingly,
reduced baseline TNF levels and NMDA-induced TNF acti-
vation in MMP-2 null mice suggested a novel in vivo role for
MMP-2 as a sheddase of TNF.The suppressed TNF signaling
in MMP-2 null mice is likely to underlie their increased
resistance to excitotoxic RGC death; however, despite ruling
out glial reactivity and laminin-mediated survival signaling,
we could not yet pinpoint the exactmechanismwhereby TNF
exerted its effects.
Interestingly, TNF has been widely recognized as an
attractive therapeutic target. Multiple (pre)clinical trials
investigating the application of anti-TNF therapies for the
treatment of multiple sclerosis, stroke, and Parkinson’s and
Alzheimer’s disease exemplify the excellence of anti-TNF
therapeutics as neuroprotective agents [65, 66]. Accordingly,
anti-TNF therapy yielded promising results in various retinal
degenerative disorders, including glaucoma, retinal ischemia,
age-related macular degeneration, and retinitis pigmentosa
[63]. Nevertheless, due to its pleiotropic effects in the CNS,
inhibition of TNF has been associated with many side effects,
which have been proposed to resolve upon selective targeting
of sTNF. Given its suspected activity as TNF sheddase,MMP-
2 might thus be an interesting target to interfere with sTNF
production. Indeed, the detrimental roles of MMPs in var-
ious neurodegenerative and (neuro)inflammatory diseases,
combined with their druggability, have made them attractive
therapeutic targets, and selective MMP-2 inhibition could
hence be an alternative for current TACE inhibitors [63, 65,
67].
Conflict of Interests
The authors have no conflict of interests.
Acknowledgments
The authors would like to thank Elien Van Wonterghem and
Lut Noterdaeme for their excellent technical assistance. This
workwas supported by theKULeuvenResearchCouncil (KU
Leuven, Belgium, BOF-OT/14/064), theHercules Foundation
(Belgium, AKUL-09-038, AKUL-13-09), the Research Foun-
dation Flanders (FWO-Vlaanderen, Belgium, G.0054.12, fel-
lowship to MSN), and the Flemish Government Agency for
Innovation by Science and Technology (IWT-Vlaanderen,
Belgium, fellowship to LDG).
References
[1] J. P. Miller, J. Holcomb, I. Al-Ramahi et al., “Matrix metallopro-
teinases are modifiers of huntingtin proteolysis and toxicity in
Huntington’s disease,” Neuron, vol. 67, no. 2, pp. 199–212, 2010.
[2] S. Rivera, M. Khrestchatisky, L. Kaczmarek, G. A. Rosenberg,
and D. M. Jaworski, “Metzincin proteases and their inhibitors:
foes or friends in nervous system physiology?” The Journal of
Neuroscience, vol. 30, no. 46, pp. 15337–15357, 2010.
[3] G. A. Rosenberg, “Matrix metalloproteinases and their multiple
roles in neurodegenerative diseases,”The Lancet Neurology, vol.
8, no. 2, pp. 205–216, 2009.
[4] V. W. Yong, “Metalloproteinases: mediators of pathology and
regeneration in the CNS,” Nature Reviews Neuroscience, vol. 6,
no. 12, pp. 931–944, 2005.
[5] M. Verslegers, K. Lemmens, I. Van Hove, and L. Moons,
“Matrix metalloproteinase-2 and -9 as promising benefactors
in development, plasticity and repair of the nervous system,”
Progress in Neurobiology, vol. 105, pp. 60–78, 2013.
[6] L. De Groef, I. Van Hove, E. Dekeyster, I. Stalmans, and L.
Moons, “MMPs in the trabecular meshwork: promising targets
for future glaucoma therapies?” Investigative Ophthalmology
and Visual Science, vol. 54, no. 12, pp. 7756–7763, 2013.
[7] L. De Groef, I. Van Hove, E. Dekeyster, I. Stalmans, and L.
Moons, “MMPs in the neuroretina and optic nerve: modulators
of glaucoma pathogenesis and repair?” Investigative Ophthal-
mology & Visual Science, vol. 55, no. 3, pp. 1953–1964, 2014.
[8] J. M. Sivak and M. E. Fini, “MMPs in the eye: emerging roles
for matrix metalloproteinases in ocular physiology,” Progress in
Retinal and Eye Research, vol. 21, no. 1, pp. 1–14, 2002.
[9] M.A.Wride, J. Geatrell, and J. A.Guggenheim, “Proteases in eye
development and disease,” Birth Defects Research Part C—
Embryo Today, vol. 78, no. 1, pp. 90–105, 2006.
[10] X. Zhang, M. Cheng, and S. K. Chintala, “Kainic acid-mediated
upregulation of matrix metalloproteinase-9 promotes retinal
degeneration,” Investigative Ophthalmology and Visual Science,
vol. 45, no. 7, pp. 2374–2383, 2004.
[11] X. Zhang, M. Cheng, and S. K. Chintala, “Optic nerve ligation
leads to astrocyte-associatedmatrixmetalloproteinase-9 induc-
tion in the mouse retina,” Neuroscience Letters, vol. 356, no. 2,
pp. 140–144, 2004.
12 Mediators of Inflammation
[12] S.-I. Manabe, Z. Gu, and S. A. Lipton, “Activation of matrix
metalloproteinase-9 via neuronal nitric oxide synthase con-
tributes to NMDA-induced retinal ganglion cell death,” Inves-
tigative Ophthalmology and Visual Science, vol. 46, no. 12, pp.
4747–4753, 2005.
[13] A. R. C. Santos, R. G. Corredor, B. A. Obeso et al., “𝛽1 integrin-
focal adhesion kinase (FAK) signaling modulates retinal gan-
glion cell (RGC) survival,” PLoS ONE, vol. 7, no. 10, Article ID
e48332, 2012.
[14] S. K. Chintala, X. Zhang, J. S. Austin, andM. E. Fini, “Deficiency
in matrix metalloproteinase gelatinase B (MMP-9) protects
against retinal ganglion cell death after optic nerve ligation,”
Journal of Biological Chemistry, vol. 277, no. 49, pp. 47461–
47468, 2002.
[15] X. Zhang and S. K. Chintala, “Influence of interleukin-1 beta
induction and mitogen-activated protein kinase phosphoryla-
tion on optic nerve ligation-induced matrix metalloproteinase-
9 activation in the retina,” Experimental Eye Research, vol. 78,
no. 4, pp. 849–860, 2004.
[16] X. Zhang, T. Sakamoto, Y. Hata et al., “Expression of matrix
metalloproteinases and their inhibitors in experimental retinal
ischemia-reperfusion injury in rats,”Experimental Eye Research,
vol. 74, no. 5, pp. 577–584, 2002.
[17] M.-H. Sun, K.-J. Chen, Y.-P. Tsao et al., “Down-regulation
of matrix metalloproteinase-9 by pyrrolidine dithiocarbamate
prevented retinal ganglion cell death after transection of optic
nerve in rats,” Current Eye Research, vol. 36, no. 11, pp. 1053–
1063, 2011.
[18] L. Guo, S. E. Moss, R. A. Alexander, R. R. Ali, F. W. Fitzke, and
M. F. Cordeiro, “Retinal ganglion cell apoptosis in glaucoma is
related to intraocular pressure and IOP-induced effects on
extracellular matrix,” Investigative Ophthalmology and Visual
Science, vol. 46, no. 1, pp. 175–182, 2005.
[19] W. Halfter, M. Willem, and U. Mayer, “Basement membrane-
dependent survival of retinal ganglion cells,” Investigative Oph-
thalmology and Visual Science, vol. 46, no. 3, pp. 1000–1009,
2005.
[20] O. A. Agapova, P. L. Kaufman, M. J. Lucarelli, B. T. Gabelt, and
M. R. Hernandez, “Differential expression of matrix metallo-
proteinases in monkey eyes with experimental glaucoma or
optic nerve transection,” Brain Research, vol. 967, no. 1-2, pp.
132–143, 2003.
[21] O. A. Agapova, C. S. Ricard, M. Salvador-Silva, and M. Rosario
Hernandez, “Expression of matrix metalloproteinases and tis-
sue inhibitors of metalloproteinases in human optic nerve head
astrocytes,” Glia, vol. 33, no. 3, pp. 205–216, 2001.
[22] K. Endo, T. Nakamachi, T. Seki et al., “Neuroprotective effect of
PACAP against NMDA-induced retinal damage in the mouse,”
Journal of Molecular Neuroscience, vol. 43, no. 1, pp. 22–29, 2011.
[23] Y. Ito, M. Shimazawa, Y. Inokuchi et al., “Degenerative alter-
ations in the visual pathway after NMDA-induced retinal
damage in mice,” Brain Research, vol. 1212, pp. 89–101, 2008.
[24] F. Lebrun-Julien, L. Duplan, V. Pernet et al., “Excitotoxic death
of retinal neurons in vivo occurs via a non-cell-autonomous
mechanism,” Journal of Neuroscience, vol. 29, no. 17, pp. 5536–
5545, 2009.
[25] N. Nakano, H. O. Ikeda, M. Hangai et al., “Longitudinal and
simultaneous imaging of retinal ganglion cells and inner retinal
layers in a mouse model of glaucoma induced by N-methyl-D-
aspartate,” Investigative Ophthalmology and Visual Science, vol.
52, no. 12, pp. 8754–8762, 2011.
[26] T. Nakazawa, M. Shimura, M. Ryu et al., “ERK1 plays a critical
protective role against N-methyl-D-aspartate-induced retinal
injury,” Journal of Neuroscience Research, vol. 86, no. 1, pp. 136–
144, 2008.
[27] T. Nakazawa, H. Takahashi, K. Nishijima et al., “Pitavastatin
prevents NMDA-induced retinal ganglion cell death by sup-
pressing leukocyte recruitment,” Journal of Neurochemistry, vol.
100, no. 4, pp. 1018–1031, 2007.
[28] L. V. Kalia, S. K. Kalia, and M. W. Salter, “NMDA receptors in
clinical neurology: excitatory times ahead,”The Lancet Neurol-
ogy, vol. 7, no. 8, pp. 742–755, 2008.
[29] R. J. Casson, “Possible role of excitotoxicity in the pathogenesis
of glaucoma,”Clinical and Experimental Ophthalmology, vol. 34,
no. 1, pp. 54–63, 2006.
[30] N. N. Osborne, M. Ugarte, M. Chao et al., “Neuroprotection in
relation to retinal ischemia and relevance to glaucoma,” Survey
of Ophthalmology, vol. 43, no. 6, pp. S102–S128, 1999.
[31] M. Seki and S. A. Lipton, “Targeting excitotoxic/free radical
signaling pathways for therapeutic intervention in glaucoma,”
Progress in Brain Research, vol. 173, pp. 495–510, 2008.
[32] T. H. Vu, J. M. Shipley, G. Bergers et al., “MMP-9/gelatinase B
is a key regulator of growth plate angiogenesis and apoptosis of
hypetrophic chondrocytes,”Cell, vol. 93, no. 3, pp. 411–422, 1998.
[33] T. Itoh, T. Ikeda, H. Gomi, S. Nakao, T. Suzuki, and S. Itohara,
“Unaltered secretion of beta-amyloid precursor protein in
gelatinase A (Matrix metalloproteinase 2)-deficient mice,” The
Journal of Biological Chemistry, vol. 272, no. 36, pp. 22389–
22392, 1997.
[34] B. Rojas, B. I. Gallego, A. I. Ramı´rez et al., “Microglia in mouse
retina contralateral to experimental glaucoma exhibit multiple
signs of activation in all retinal layers,” Journal of Neuroinflam-
mation, vol. 11, article 133, 2014.
[35] A. I. Ramı´rez, J. J. Salazar, R. de Hoz et al., “Quantification of
the effect of different levels of IOP in the astroglia of the rat
retina ipsilateral and contralateral to experimental glaucoma,”
Investigative Ophthalmology and Visual Science, vol. 51, no. 11,
pp. 5690–5696, 2010.
[36] B. I. Gallego, J. J. Salazar, R. de Hoz et al., “IOP induces
upregulation of GFAP and MHC-II and microglia reactivity in
mice retina contralateral to experimental glaucoma,” Journal of
Neuroinflammation, vol. 9, no. 92, pp. 1742–2094, 2012.
[37] G. Parrilla-Reverter, M. Agudo, F. Nadal-Nicola´s et al., “Time-
course of the retinal nerve fibre layer degeneration after
complete intra-orbital optic nerve transection or crush: a
comparative study,” Vision Research, vol. 49, no. 23, pp. 2808–
2825, 2009.
[38] L. De Groef, K. Lemmens, I. Van Hove, and L. Moons, “Matrix
metalloproteinases in the mouse retina: a comparative study of
expression patterns and anti-MMP antibodies,” BMC Ophthal-
mology, In press.
[39] C. Galindo-Romero, M. Avile´s-Trigueros, M. Jime´nez-Lo´pez et
al., “Axotomy-induced retinal ganglion cell death in adult mice:
quantitative and topographic time course analyses,” Experimen-
tal Eye Research, vol. 92, no. 5, pp. 377–387, 2011.
[40] M. Vidal-Sanz, M. Salinas-Navarro, F. M. Nadal-Nicola´s et al.,
“Understanding glaucomatous damage: anatomical and func-
tional data from ocular hypertensive rodent retinas,” Progress in
Retinal and Eye Research, vol. 31, no. 1, pp. 1–27, 2012.
[41] J. Schindelin, I. Arganda-Carreras, E. Frise et al., “Fiji: an open-
source platform for biological-image analysis,”Nature Methods,
vol. 9, no. 7, pp. 676–682, 2012.
Mediators of Inflammation 13
[42] L. Taylor, K.Arner, and F.Ghosh, “First responders: dynamics of
pre-gliotic muller cell responses in the isolated adult rat retina,”
Current Eye Research, vol. 11, pp. 1–16, 2014.
[43] G. Tezel, “TNF-𝛼 signaling in glaucomatous neurodegenera-
tion,” in Progress in Brain Research, B. Giacinto and L. C. N. N.
O. Carlo Nucci, Eds., pp. 409–421, Elsevier, 2008.
[44] M. D. Sternlicht and Z. Werb, “How matrix metalloproteinases
regulate cell behavior,”Annual Review ofCell andDevelopmental
Biology, vol. 17, pp. 463–516, 2001.
[45] A. J. Gearing, P. Beckett, M. Christodoulou et al., “Matrix
metalloproteinases and processing of pro-TNF-alpha,” Journal
of Leukocyte Biology, vol. 57, no. 5, pp. 774–777, 1995.
[46] J. Vandooren,N.Geurts, E.Martens, P. E. VanDen Steen, andG.
Opdenakker, “Zymography methods for visualizing hydrolytic
enzymes,” Nature Methods, vol. 10, no. 3, pp. 211–220, 2013.
[47] A. Reichenbach and A. Bringmann,Mu¨ller Cells in the Healthy
and Diseased Retina, Springer, New York, NY, USA, 2010.
[48] F. R. Va´zquez-Chona, A. Swan,W. D. Ferrell et al., “Proliferative
reactive gliosis is compatible with glial metabolic support and
neuronal function,” BMC Neuroscience, vol. 12, no. 1, article 98,
2011.
[49] R. Vohra, J. C. Tsai, and M. Kolko, “The role of inflammation
in the pathogenesis of glaucoma,” Survey of Ophthalmology, vol.
58, no. 4, pp. 311–320, 2013.
[50] J.-Y. C. Hsu, R. McKeon, S. Goussev et al., “Matrix metallo-
proteinase-2 facilitates wound healing events that promote
functional recovery after spinal cord injury,” The Journal of
Neuroscience, vol. 26, no. 39, pp. 9841–9850, 2006.
[51] M. M. Edwards and S. R. Robinson, “TNF alpha affects the
expression of GFAP and S100B: implications for Alzheimer’s
disease,” Journal of Neural Transmission, vol. 113, no. 11, pp.
1709–1715, 2006.
[52] K. Selmaj, B. Shafit-Zagardo, D. A. Aquino et al., “Tumor
necrosis factor-induced proliferation of astrocytes frommature
brain is associated with down-regulation of glial fibrillary acidic
protein mRNA,” Journal of Neurochemistry, vol. 57, no. 3, pp.
823–830, 1991.
[53] M. J. Mohan, T. Seaton, J. Mitchell et al., “The tumor necrosis
factor-alpha converting enzyme (TACE): a unique metallopro-
teinase with highly defined substrate selectivity,” Biochemistry,
vol. 41, no. 30, pp. 9462–9469, 2002.
[54] C. M. Overall and C. P. Blobel, “In search of partners: linking
extracellular proteases to substrates,” Nature Reviews Molecular
Cell Biology, vol. 8, no. 3, pp. 245–257, 2007.
[55] R. E. Vandenbroucke, E. Dejonckheere, F. VanHauwermeiren et
al., “Matrix metalloproteinase 13 modulates intestinal epithelial
barrier integrity in inflammatory diseases by activating TNF,”
EMBOMolecular Medicine, vol. 5, no. 7, pp. 932–948, 2013.
[56] M. Fanjul-Ferna´ndez, A. R. Folgueras, S. Cabrera, andC. Lo´pez-
Ot´ın, “Matrix metalloproteinases: evolution, gene regulation
and functional analysis in mouse models,” Biochimica et Bio-
physica Acta—Molecular Cell Research, vol. 1803, no. 1, pp. 3–19,
2010.
[57] Y.-P. Han, T.-L. Tuan, H. Wu, M. Hughes, and W. L. Garner,
“TNF-alpha stimulates activation of pro-MMP2 in human
skin through NF-(kappa)B mediated induction of MT1-MMP,”
Journal of Cell Science, vol. 114, part 1, pp. 131–139, 2001.
[58] G. Tezel, L. Y. Li, R. V. Patil, and M. B. Wax, “TNF-𝛼 and TNF-
𝛼 receptor-1 in the retina of normal and glaucomatous eyes,”
Investigative Ophthalmology & Visual Science, vol. 42, no. 8, pp.
1787–1794, 2001.
[59] L. Yuan and A. H. Neufeld, “Tumor necrosis factor-𝛼: a
potentially neurodestructive cytokine produced by glia in the
human glaucomatous optic nerve head,”GLIA, vol. 32, no. 1, pp.
42–50, 2000.
[60] G. Olmos and J. Llado´, “Tumor necrosis factor alpha: a link
between neuroinflammation and excitotoxicity,” Mediators of
Inflammation, vol. 2014, Article ID 861231, 12 pages, 2014.
[61] A. Bringmann, A. Grosche, T. Pannicke, and A. Reichenbach,
“GABA and glutamate uptake and metabolism in retinal glial
(mu¨ller) cells,” Frontiers in Endocrinology, vol. 4, article 48, 2013.
[62] S. Tilleux and E. Hermans, “Neuroinflammation and regulation
of glial glutamate uptake in neurological disorders,” Journal of
Neuroscience Research, vol. 85, no. 10, pp. 2059–2070, 2007.
[63] M. M. Al-Gayyar and N. M. Elsherbiny, “Contribution of
TNF-alpha to the development of retinal neurodegenerative
disorders,” European Cytokine Network, vol. 24, no. 1, pp. 27–36,
2013.
[64] G. Tezel, X. Yang, J. Yang, andM. B.Wax, “Role of tumor necro-
sis factor receptor-1 in the death of retinal ganglion cells follow-
ing optic nerve crush injury in mice,” Brain Research, vol. 996,
no. 2, pp. 202–212, 2004.
[65] M. K. McCoy and M. G. Tansey, “TNF signaling inhibition in
the CNS: implications for normal brain function and neurode-
generative disease,” Journal of Neuroinflammation, vol. 5, article
45, 2008.
[66] D. Tweedie, K. Sambamurti, and N. H. Greig, “TNF-𝛼 inhibi-
tion as a treatment strategy for neurodegenerative disorders:
new drug candidates and targets,” Current Alzheimer Research,
vol. 4, no. 4, pp. 378–385, 2007.
[67] R. E. Vandenbroucke and C. Libert, “Is there new hope for ther-
apeutic matrix metalloproteinase inhibition?” Nature Reviews
Drug Discovery, vol. 13, no. 12, pp. 904–927, 2014.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
